A TP53 gene mutation has been reported to boost PD-L1 expression, facilitate T-cell infiltration, and augment tumor immunogenicity and is a potential predictive marker for response to ICIs in LUAD (Dong et al., 2017). This evidence concerns the gene TP53 and neoplasm.